BiotechTube
EraCal Therapeutics

EraCal Therapeutics

Zurich, Switzerland· Est.
eracal.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35.5M

Overview

EraCal Therapeutics is a privately held, preclinical-stage biotech company leveraging a high-throughput zebrafish phenotypic screening platform to discover novel appetite modulators for obesity and metabolic diseases. The company has gained significant validation through strategic collaborations and a major licensing deal with Novo Nordisk, positioning it as a notable player in the cardiometabolic space. Founded in 2018 and backed by specialized life science investors, EraCal has been consistently recognized as a top Swiss startup and is advancing its lead program, Era-107, towards clinical development.

ObesityMetabolic Disorders

Technology Platform

Proprietary high-throughput phenotypic screening platform using zebrafish (Danio rerio) to measure complex behaviors like food intake and energy expenditure for novel target and drug discovery.

Funding History

2
Total raised:$35.5M
Series A$29M
Seed$6.5M

Opportunities

The global obesity drug market is expanding rapidly, creating demand for novel oral therapies with complementary mechanisms to existing injectables.
EraCal's phenotypic platform can uncover first-in-class biology, enabling potential best-in-class assets and creating opportunities for further lucrative partnerships or acquisitions in metabolic disease and beyond.

Risk Factors

High translational risk exists as novel targets identified in zebrafish may not prove effective or safe in humans.
The company faces intense competition from large pharma with significant resources in the obesity space.
Dependency on a lead preclinical asset (Era-107) and on the success of the Novo Nordisk partnership creates concentrated development and strategic risk.

Competitive Landscape

EraCal operates in the highly competitive obesity therapeutics market, dominated by large players like Novo Nordisk and Eli Lilly. Its differentiation lies in its novel phenotypic discovery approach, which aims to identify unexplored targets, potentially leading to drugs with unique efficacy or safety profiles. However, it competes with numerous other biotechs also pursuing next-generation anti-obesity mechanisms.

More companies in Switzerland →